Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$20.7K Buy
301
+32
+12% +$2.13K ﹤0.01% 1123
2026
Q1
$16.7K Sell
269
-9
-3% -$627 ﹤0.01% 1214
2025
Q4
$18.8K Buy
278
+6
+2% +$388 ﹤0.01% 949
2025
Q3
$18.2K Buy
272
+68
+33% +$5.38K ﹤0.01% 873
2025
Q2
$17.1K Buy
204
+160
+364% +$12.5K ﹤0.01% 412
2025
Q1
$3K Hold
44
﹤0.01% 556
2024
Q4
$3.42K Hold
44
﹤0.01% 540
2024
Q3
$2.95K Buy
+44
New +$3.61K ﹤0.01% 573
2020
Q2
Sell
-520
Closed -$35K 112
2020
Q1
$35K Buy
+520
New +$32.4K 0.01% 108

Other funds holding DXCM

Salomon & Ludwin's DXCM Position: Q2 2026 in Review

Salomon & Ludwin increased its DexCom (DXCM) stake by 12% in Q2 2026, buying an estimated $2.13K and bringing the position to 301 shares worth $20.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1123.

Salomon & Ludwin first reported a position in DXCM in Q1 2020 and has held it in 9 quarters since. The position peaked at $35K in Q1 2020. 974 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Salomon & Ludwin held 301 shares of DexCom worth $20.7K as of Q2 2026.
  • Salomon & Ludwin bought 32 DexCom shares in Q2 2026, an estimated $2.13K.
  • DexCom made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #1123 holding.
  • Salomon & Ludwin first reported a position in DexCom in Q1 2020 and has held it in 9 quarters since.
  • Salomon & Ludwin's DexCom position peaked at $35K in Q1 2020.
  • 974 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.